Olmetab Plus
Generic Name
Olmesartan Medoxomil + Hydrochlorothiazide
Manufacturer
Square Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| olmetab plus 20 mg tablet | ৳ 7.00 | ৳ 70.00 |
| olmetab plus 40 mg tablet | ৳ 12.00 | ৳ 120.00 |
Description
Overview of the medicine
Olmetab Plus is a combination medicine containing Olmesartan Medoxomil, an angiotensin II receptor blocker (ARB), and Hydrochlorothiazide, a thiazide diuretic. It is used to treat high blood pressure (hypertension) when monotherapy is not sufficient. This combination helps to lower blood pressure effectively, reducing the risk of heart attacks and strokes.
Uses & Indications
Dosage
Adults
Usually 1 tablet (Olmesartan 20 mg / Hydrochlorothiazide 12.5 mg) once daily. If necessary, the dose can be increased after 2-4 weeks to a maximum of 40 mg Olmesartan / 25 mg Hydrochlorothiazide once daily.
Elderly
No specific dose adjustment is usually required, but caution is advised with severe renal or hepatic impairment.
Renal_impairment
Not recommended for patients with severe renal impairment (creatinine clearance <30 mL/min). For moderate impairment, caution is advised and regular monitoring is necessary.
How to Take
Take orally, once daily, with or without food. Swallow the tablet whole with water. Do not crush or chew.
Mechanism of Action
Olmesartan Medoxomil selectively blocks the binding of angiotensin II to the AT1 receptor, inhibiting vasoconstriction and aldosterone secretion, leading to a reduction in blood pressure. Hydrochlorothiazide increases the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules, which also contributes to blood pressure reduction.
Pharmacokinetics
Onset
Onset of antihypertensive effect within 2 hours, maximal effect within 2-4 weeks.
Excretion
Olmesartan is primarily excreted unchanged in bile (50-65%) and urine (30-35%). Hydrochlorothiazide is primarily excreted unchanged in urine.
Half life
Olmesartan: 10-15 hours; Hydrochlorothiazide: 5.6-14.8 hours.
Absorption
Olmesartan medoxomil is rapidly and completely converted to olmesartan during absorption from the gastrointestinal tract. Hydrochlorothiazide is absorbed from the GI tract.
Metabolism
Olmesartan medoxomil is completely hydrolyzed to olmesartan; minimal metabolism of olmesartan itself. Hydrochlorothiazide is not metabolized.
Side Effects
Contraindications
- •Hypersensitivity to Olmesartan, Hydrochlorothiazide, or sulfonamide-derived drugs.
- •Anuria (absence of urine production).
- •Severe renal impairment (creatinine clearance <30 mL/min).
- •Severe hepatic impairment, biliary obstruction.
- •Pregnancy (second and third trimesters).
- •Concomitant use with aliskiren in patients with diabetes mellitus or renal impairment.
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity.
Corticosteroids, ACTH
May intensify electrolyte depletion, particularly hypokalemia.
Other antihypertensive agents
Additive hypotensive effects.
Colestyramine and colestipol resins
May impair absorption of hydrochlorothiazide.
NSAIDs (Non-steroidal anti-inflammatory drugs)
May reduce the antihypertensive effects and increase the risk of renal function deterioration.
Potassium-sparing diuretics, potassium supplements, or potassium-containing salt substitutes
May lead to hyperkalemia.
Storage
Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.
Overdose
Symptoms of overdose include hypotension (low blood pressure), dizziness, electrolyte disturbances (e.g., hypokalemia, hypochloremia), and dehydration. Management is primarily symptomatic and supportive, including maintaining hydration and monitoring electrolyte levels. In case of recent ingestion, gastric lavage or induced emesis may be considered.
Pregnancy & Lactation
Olmetab Plus is contraindicated in the second and third trimesters of pregnancy due to the risk of fetal harm and death. It is not recommended during the first trimester. It is unknown if olmesartan or hydrochlorothiazide is excreted in human milk; caution is advised or discontinue the drug while nursing.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 months
Availability
Pharmacies, Hospitals
Approval Status
Approved
Patent Status
Off-patent (Generics available)
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in